Dyne Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference

Rhea-AI Summary

Dyne Therapeutics (Nasdaq: DYN) announced its participation in the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, at 2:15 p.m. ET. The event will feature a fireside chat with management, focusing on the company’s innovative therapeutics for muscle diseases. A live webcast will be available on Dyne's website, with a replay accessible for 90 days post-event. Dyne Therapeutics specializes in developing oligonucleotide therapies targeting serious muscle disorders, utilizing its proprietary FORCE™ platform.

WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference being held in New York, NY on Monday, September 12, 2022 at 2:15 p.m. ET.

A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue seen with other approaches. Dyne has a broad portfolio of programs for serious muscle diseases, including candidates for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com/, and follow us on Twitter, LinkedIn and Facebook.

Contact:

Dyne Therapeutics
Amy Reilly
areilly@dyne-tx.com
857-341-1203

 

FAQ

What date is Dyne Therapeutics participating in the Morgan Stanley Healthcare Conference?

Dyne Therapeutics is participating in the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022.

What time will Dyne Therapeutics' presentation occur at the conference?

The presentation by Dyne Therapeutics is scheduled for 2:15 p.m. ET.

How can I watch Dyne Therapeutics' conference presentation?

You can watch Dyne Therapeutics' presentation live via webcast on their Investors & Media page, with a replay available for 90 days.

What is the focus of Dyne Therapeutics?

Dyne Therapeutics focuses on developing innovative therapeutics for genetically driven muscle diseases.

What platform does Dyne Therapeutics use for its drug development?

Dyne Therapeutics uses its proprietary FORCE™ platform for developing oligonucleotide therapeutics.